A site investigator in the failed phase III study by Taurx Therapeutics Ltd. told BioWorld Today that Alzheimer's disease (AD) "absolutely" will best be attacked by a combination approach, despite the finding that tau aggregation blocker LMTX when used along with the standard, "modestly" beneficial AD drugs "doesn't add any value."